Deoxycytidylate deaminase in the diagnosis of acute myocardial infarction.
The diagnostic value of deoxycytidylate deaminase (dCMP) in the diagnosis of acute myocardial infarction (AMI) was examined in 31 healthy controls and 32 patients with proven AMI. Its specificity in normal controls was 93.5%. Its highest levels were measured on the 3rd to 5th post-infarct day, when its sensitivity reached 97.5%. Its diagnostic performance was similar to that of SGOT, total LDH1/LDH2 ratio greater than 1, total CPK and CPK-MB. Its peak levels showed a highly significant correlation (p less than 0.001) with those of the above enzymes. The measurement of dCMP may be a valuable complement in the diagnosis of AMI since this enzyme is not affected by lung infarction or hemolysis. Moreover, since it expresses tissue regeneration rather than destruction it may aid in the assessment of various interventions designed for the promotion of myocardial healing process.[1]References
- Deoxycytidylate deaminase in the diagnosis of acute myocardial infarction. Georgiades, C., Cokkinos, D.V., Kalofoutis, A., Miras, C. Acta cardiologica. (1985) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
